文献速递白血病

Ph样急性淋巴细胞白血病:成人中的高危亚型

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
PubMed 文献 · Blood · 2016-12-05

在MD安德森癌症中心接受一线化疗的148例初诊B细胞急性淋巴细胞白血病成人患者中,33.1%为Ph样ALL,31.1%为Ph+,35.8%为其他B-ALL亚型。Ph样ALL患者总生存显著劣于其他B-ALL亚型,5年生存率23%对59%(P=.006)。

要点

  • 成人B-ALL中Ph样ALL占33.1%,Ph样ALL患者5年生存率23%,显著低于其他B-ALL的59%(P=.006)。
  • Ph样ALL患者中68%为西班牙裔,61%存在CRLF2过表达。
  • 多因素分析中Ph样ALL与更差总生存相关(HR 1.818,P=.03)。

核心结论

  • 成人中Ph样ALL频率高,西班牙裔成人中频率增加,Ph样ALL成人患者结局显著更差,CRLF2+亚组结局显著更差,需要新策略改善这些患者的结局。

研究设计与样本

  • 在MD安德森癌症中心接受一线化疗的初诊B细胞ALL成人患者,对白血病细胞进行基因表达谱分析,共148例。

主要发现

  • 148例中33.1%为Ph样,31.1%为Ph+,35.8%为其他B-ALL亚型(B-other)。
  • Ph样ALL队列中61%存在细胞因子受体样因子2(CRLF2)过表达。
  • Ph样ALL患者总生存和无事件生存显著劣于B-other,5年生存率23%(B-other为59%,P=.006)。
  • Ph样ALL患者中68%为西班牙裔。
  • 多因素分析中与更差总生存相关的因素:年龄(HR 3.299,P<.001)、白细胞计数(HR 1.910,P=.017)、血小板计数(HR 7.437,P=.005)、Ph样ALL(HR 1.818,P=.03)。

关键数值与推荐

  • Ph样ALL 5年生存率23% vs B-other 59%(P=.006)。
  • 多因素分析中年龄HR 3.299(P<.001)、白细胞计数HR 1.910(P=.017)、血小板计数HR 7.437(P=.005)、Ph样ALL HR 1.818(P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph-like ALL in adults. Patients with newly diagnosed B-cell ALL (B-ALL) who received frontline chemotherapy at MD Anderson Cancer Center underwent gene expression profiling of leukemic cells. Of 148 patients, 33.1% had Ph-like, 31.1% had Ph+, and 35.8% had other B-ALL subtypes (B-other). Within the Ph-like ALL cohort, 61% had cytokine receptor-like factor 2 (CRLF2) overexpression. Patients with Ph-like ALL had significantly worse overall survival (OS), and event-free survival compared with B-other with a 5-year survival of 23% (vs 59% for B-other, P = .006). Sixty-eight percent of patients with Ph-like ALL were of Hispanic ethnicity. The following were associated with inferior OS on multivariable analysis: age (hazard ratio [HR], 3.299; P < .001), white blood cell count (HR, 1.910; P = .017), platelet count (HR, 7.437; P = .005), and Ph-like ALL (HR, 1.818; P = .03). Next-generation sequencing of the CRLF2+ group identified mutations in the JAK-STAT and Ras pathway in 85% of patients, and 20% had a CRLF2 mutation. Within the CRLF2+ group, JAK2 mutation was associated with inferior outcomes. Our findings show high frequency of Ph-like ALL in adults, an increased frequency of Ph-like ALL in adults of Hispanic ethnicity, significantly inferior outcomes of adult patients with Ph-like ALL, and significantly worse outcomes in the CRLF2+ subset of Ph-like ALL. Novel strategies are needed to improve the outcome of these patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2016. PMID: 27919910. doi:10.1182/blood-2016-07-726588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。